Chicago, IL—Oncologists looking to learn about immunotherapy did not have to go very far at the 2015 American Society of Clinical Oncology meeting. Many of the highest-impact presentations this year, including a plenary session, the Karnofsky Award, and the Science of Oncology Award, focused on cancer therapy’s most exciting field.
Oncologists’ excitement about the promise of immunotherapy is about to be tested in clinical practice, with the recent FDA approval of pembrolizumab (Kytruda; Merck), the first anti–programmed death receptor-1 (PD-1) monoclonal antibody

Results 1 - 3 of 3
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology